Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia
Updated: Aug 23, 2022
January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for our lead compound #dipraglurant in #PDLID (#Parkinsonsdisease levodopa-induced #dyskinesia)."